Skip to main content
. Author manuscript; available in PMC: 2009 Feb 20.
Published in final edited form as: Vaccine. 2008 Jan 10;26(8):1098–1110. doi: 10.1016/j.vaccine.2007.12.024

Figure 1.

Figure 1

DP6−001 formulation induced HIV-1 specific cell-mediated immune responses in volunteers' PBMC. (a) Group averages of Env- and Gag-specific IFNγ ELISPOT responses at different time points following DNA or protein immunizations (see Table 2 for standard error and percentage of responders). The solid arrows indicate DNA immunizations and the open arrows indicate protein immunizations. Pools of overlapping peptides from either gp120 antigens of subtype A isolate 92UG037.8 (Env-A) and subtype B isolate 92US715.6 (Env-B) or Gag antigen of subtype C isolate 96ZM651 (Gag) were used for the assay. (b) HIV-1-specific IFNγ ELISPOT responses were detected at 2 weeks after either the 3rd DNA immunization (DNA-3), the 1st or 2nd protein boosts (Prot-1 and Prot-2), or at Week 52 (Closeout) against pools overlapping peptides from gp120 antigens of subtype C isolate 96ZM651 (Env-C) and subtype E isolate 93TH976.17 (Env-E). Results are shown as responses from each of six randomly selected volunteers in each group as well as the group average (short horizontal bars).